Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application

FDA indicated to Schering-Plough that the firm's Rx-to-OTC switch application for the proton pump inhibitor Zegerid is not ready for approval

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet